Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

LSD-assisted therapy resulted in durable anxiety improvement in Phase 2 study

By Brian Buntz | September 8, 2022

LSD

[Image courtesy of PubChem]

A randomized placebo-controlled Phase 2 study found that lysergic acid diethylamide (LSD)–assisted therapy yielded significant reductions in anxiety and depression symptoms for up to 16 weeks.

The data from the study was recently published in the peer-reviewed Biological Psychiatry.

Researchers at the University Hospital Basel (UHB) conducted the investigator-initiated study, which involved 42 patients.

While there was a substantial amount of research on LSD-assisted therapy in the 1950s and 1960s, psilocybin has emerged as a more popular compound for psychedelic-based therapy in recent years.

In the data published in Biological Psychiatry, researchers used Spielberger’s State-Trait Anxiety Inventory–Global (STAI-G) score and the HAM-D-21 (Hamilton Depression Rating Scale) to quantify anxiety and depression, respectively. Investigators also used the Beck Depression Inventory (BDI) in the study.

Patients who received LSD-assisted therapy had a 16.2 point drop in STAI-G scores at 16 weeks after treatment. Similarly, LSD recipients had a 7.0 point drop in the HAM-D-21 test and a 6.1 point drop on the BDI.

LSD was generally well tolerated in the study, but 19% of patients reported transient negative side effects from the LSD treatment. One patient had a treatment-related serious adverse event (acute transient anxiety).

The psychedelic medicine firm MindMed (Nasdaq:MNMD) is touting the positive data as it moves forward with a Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized type of LSD. MindMed believes that the data from the UHB study supports the clinical development of its proprietary formulation of LSD.

MindMed has an exclusive multi-year research partnership with UHB and holds exclusive rights to the university’s research on LSD and related compounds.

“This was an investigator-initiated Phase 2 study led by MindMed collaborators at University Hospital Basel (UHB), Dr. Frederike Holze and Prof. Dr. Matthias Liechti which further reinforces the positive preliminary evidence for LSD in patients who suffer from anxiety disorders,” said MindMed CEO Robert Barrow. “MindMed has a broad, multi-year exclusive research partnership with UHB in addition to exclusive worldwide rights to the data, compounds and patent rights associated with UHB’s research on LSD and other compounds.”

LSD remains a Schedule I drug in the U.S., meaning that the federal government believes it to have no accepted medical use with a high potential for abuse.

The federal government, however, may be warming to the prospect of psychedelic-assisted therapy to combat spiraling rates of depression and anxiety. A leaked SAMHSA letter indicates that FDA is likely to approve in the coming years.

National Institute on Drug Abuse (NIDA) Director Nora Volkow said in an NIH psychedelic workshop that the “train has left the station” regarding the therapeutic use of psychedelics. A letter from several members of Congress dated February 11, 2022 indicates that the FDA would likely approve MDMA for PTSD and psilocybin for depression within approximately 24 months.


Filed Under: Psychiatric/psychotropic drugs
Tagged With: anxiety, depression, LSD, LSD-assisted therapy, lysergic acid diethylamide, MindMed
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE